North America Glucagon-Like Peptide-1 (GLP-1) Agonist Market Size, Share, Forecasts to 2032

GLP-1 receptor agonists (GLP-1RAs) are a kind of pharmaceutical used to treat type 2 diabetes, and some are also authorized to treat obesity. This family of medicines has a reduced risk of producing hypoglycemia than sulfonylureas or meglitinides. GLP-1RAs have considerable anti-inflammatory and pulmonary protective effects, as well as a favorable influence on the makeup of gut bacteria.

North America Glucagon-Like Peptide-1 (GLP-1) Agonist Market Size, Share, Forecasts to 2032

GLP-1 receptor agonists (GLP-1RAs) are a kind of pharmaceutical used to treat type 2 diabetes, and some are also authorized to treat obesity. This family of medicines has a reduced risk of producing hypoglycemia than sulfonylureas or meglitinides. GLP-1RAs have considerable anti-inflammatory and pulmonary protective effects, as well as a favorable influence on the makeup of gut bacteria.